Bronchopulmonary dysplasia. Impact of surfactant replacement therapy.
Bronchopulmonary dysplasia is a major contributor to the morbidity and mortality of infants born prematurely. Surfactant replacement therapy has had a significant impact on the death rate from respiratory distress syndrome, yet the impact on bronchopulmonary dysplasia is minimal. Despite these findings, the overall incidence and severity of bronchopulmonary dysplasia are likely to decline over time as neonatal care continues to advance.
McColley
S A
SA
Cystic Fibrosis Center, Children's Memorial Medical Center, Chicago, Illinois, USA.
D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal / Q000379:methods / Q000639:trends; D009017:Morbidity; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D011663:Pulmonary Surfactants